BioNTech US Inc.

BioNTech US Inc. operates as a clinical-stage immuno-oncology company that develops neoantigen-targeted therapies for cancer. It offers NEO-PV-01, a neoantigen vaccine for the treatment of metastatic non-small cell lung cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; NEO-SV-01, a neoantigen vaccine for the treatment of hormone receptor-positive breast cancer; and NEO-STC-01, a neoantigen adoptive T cell therapy for the treatment of cancers driven or mediated by RAS mutations. BioNTech US Inc. was formerly known as Neon Therapeutics, Inc. and changed its name to BioNTech US Inc. in May 2020. The company was incorporated in 2013 and is based in Cambridge, Massachusetts, with additional locations across the globe. As of May 7, 2020, BioNTech US Inc. operates as a subsidiary of BioNTech SE.